(MENAFN- PR Newswire)
DUBLIN, Feb. 16, 2022 /PRNewswire/ -- The 'Global Organ Transplantation Market (2021-2026) by Treatment, Organ, Product, Transplant, End User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis' report has been added to ResearchAndMarkets.com's offering.
The Global Organ Transplantation Market is estimated to be USD 12.95 Bn in 2021 and is expected to reach USD 22.1 Bn by 2026, growing at a CAGR of 11.28%.Factors for Driving the market are demand for tissue and organ plantation is high for organ failure treatment. Organ failure occurs due to various factors such as frivolous trauma, loss of blood, poisoning, drug abuse, etc. The increasing prevalence of renal disease, overconsumption of alcohol, and unhealthy diet have provided a push for the growth of the Organ Transplantation market. Huge population suffering from chronic illness and organ failure.
Treatment of failure contributing to the development and Technological advancement and increasing issue banks are also boosting the market. A rise in demand for organ replacement, mainly kidney, heart, liver, is very high globally. High cost for transplantation including, the expensiveness of the accomplished services, the limited number of donors available, the number of failures that happen, hampers the market. An increasing incidence of organ failure creates tension among patients. The challenges are the Shortage of resources available in the market.The Global Organ Transplantation Market is segmented based on Treatment, Organ, Product, Transplant, End User, and Geography. Countries Studied
- America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
- Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
- Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
- Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)
Competitive Quadrant
The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc. Why buy this report?
- The report offers a comprehensive evaluation of the Global Organ Transplantation Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
- The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
- The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
- The report also contains the competitive analysis using a Competitive Quadrant, Infogence's proprietary competitive positioning tool.
Report Highlights:
- A complete analysis of the market, including parent industry
- Important market dynamics and trends
- Market segmentation
- Historical, current, and projected size of the market based on value and volume
- Market shares and strategies of key players
- Recommendations to companies for strengthening their foothold in the market
Key Topics Covered: 1 Report Description 2 Research Methodology 3 Executive Summary 3.1 Introduction3.2 Market Size and Segmentation3.3 Market Outlook 4 Market Influencers 4.1.1.1 Drivers4.1.1.2 High Demand for Tissue and Organ Plantation 4.1.1.3 Increasing Prevalence of Renal Disease 4.1.1.4 Large Population Suffering from Chronic Diseases 4.1.2 Restraints4.1.2.1 High Cost of Transplantation 4.1.2.2 Increasing Incident of Organ Failure 4.1.3 Opportunities4.1.3.1 Treatment of Failure Contributing to Growth 4.1.3.2 Technological Advancement and Increasing Issue Banks 4.1.3.3 The Rise in Demand of Organ Replacement4.1.4 Challenges4.1.4.1 Shortage of Resources 4.1.4.2 Large and Scarce Competition 4.1.4.3 Impact of Domestic Tariffs 5 Market Analysis 5.1 Porter's Five Forces Analysis5.2 Impact of COVID-195.3 Ansoff Matrix Analysis 6 Global Organ Transplantation Market, By Organ Type 6.1 Introduction6.2 Heart 6.3 Kidney6.4 Liver 6.5 Lungs 6.6 Other 7 Global Organ Transplantation Market, By Product Type 7.1 Introduction7.2 Organ Preservation Solution 7.3 Transplant Diagnostics 7.4 Tissue Products 7.5 Other 8 Global Organ Transplantation Market, By Transplant Type 8.1 Introduction8.2 Autograft 8.3 Allograft and Allotransplantation 8.4 Xenograft 8.5 Xenotransplantation 8.6 Other 9 Global Organ Transplantation Market, By Treatment Type 9.1 Introduction9.2 Analgesic 9.3 Immunosuppressant 9.3.1 Calcineurin inhibitors 9.3.1.1 Tacrolimus 9.3.1.2 Cyclosporine 9.3.2 mTOR inhibitor 9.3.2.1 Sirolimus 9.3.2.2 Everolimus 9.3.3 Antiproliferative agents 9.3.4 Steroids 9.3.5 Other 9.4 Other 10 Global Organ Transplantation Market, By End User Type 10.1 Introduction10.2 Hospitals 10.3 Transplant Centers 10.4 Others 11 Global Organ Transplantation Market, By Geography
12 Competitive Landscape 12.1 Competitive Quadrant12.2 Market Share Analysis12.3 Strategic Initiatives12.3.1 M&A and Investments12.3.2 Partnerships and Collaborations12.3.3 Product Developments and Improvements 13 Company Profiles 13.1 Novartis International AG13.2 Terumo Medical Corporation 13.3 Transonic 13.4 F. Hoffmann-La Roche Ltd. 13.5 Astellas Pharma Inc. 13.6 Preservation Solutions, Inc. 13.7 OrganOX Limited 13.8 Bio-Med Pvt. Ltd.13.9 Transplant Biomedical 13.10 TransMedic Inc. 13.11 Accord healthcare GmbH 13.12 Sanofi 13.13 Pfizer Inc. 13.14 Veloxis Pharmaceuticals 13.15 GlaxoSmithKline plc. 13.16 Medtronic 13.17 Terumo corporation 13.18 AbbVie Inc. 13.19 Stryker13.20 Zimmer Biomet13.21 Organdonor.gov13.22 NHS Blood and transplant 13.23 21st-century medicine 13.24 Biolife solutions 13.25 Teva pharmaceutical 13.26 Veloxis pharmaceutical 14 Appendix
For more information about this report visit
Media Contact:
Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
MENAFN16022022003732001241ID1103713153
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.